Androgen Receptor Inhibitor to Provoke Better Survival Response in Metastatic Castration-Sensitive Prostate Cancer

Release Date: 23-Nov-2020

All the recent findings that have been conducted for the treatment of metastatic castration-sensitive prostate cancer (mCSPC) has completely re-shaped the entire treatment regimen available. The recent clinical trial study with respect to same cancer type is pointing towards the use and benefits of second-generation androgen receptor (AR) inhibitors in the treatment of metastatic castration-sensitive prostate cancer. As per the research conducted for the cancer throughout the years, it has been concluded that most of the patients develop the cancer due to the reactivation of androgen receptor signalling.

The clinical trial with respect to the same cancer is investigating the drug Abiraterone as a potential therapy for the treatment. The clinical research study was focused towards deriving the benefits of abiraterone acetate (Zytiga) in combination with standard therapy when compared with the other therapies. Some of the primary aims of the clinical research study was to evaluate overall survival, failure-free survival (FFS), toxicity, quality of life (QOL), skeletal-related events, and cost effectiveness. In one group of participants enrolled in the respective study who received ADT plus abiraterone showed 37% improvement in OS.

Also, the researchers involved in the respective study reported 55% reduction in symptomatic skeletal-related events with the combination versus ADT alone. The respective clinical trial that was conducted for the same is witnessed to be first clinical research study focused towards evaluating the healthcare benefits of abiraterone in the patients suffering from metastatic prostate cancer. The whole outcome associated with the clinical research study made it clear that this respective treatment could be used as a novel tool for treating the patients as there was 71% improvement in failure free survival in the patients who received the drug when compared with the patients who only received standard of care.